One Health Group’s H2 Trading Stays Strong – Guidance Held, Revenue Tracking High End
One Health Group has confirmed a steady-as-she-goes second half, with full-year revenue and underlying EBITDA for FY26 set to land in line with market expectations – and revenue at the higher end of consensus. The tone is confident, the outlook unchanged, and operational indicators continue to move the right way.
On top of that, the first new-build surgical hub is close to clearing its final pre-commencement planning condition (environmental), with contractors ready to go and a one-year build timetable anticipated. Management says this hub has the potential to materially lift revenue and profitability once operational.
FY26 guidance: what “in line” really means
Management cites consensus forecasts for FY26 revenue of £29.2 million to £29.6 million, and underlying EBITDA of £2.3 million. The Company expects to be at the higher end of the revenue range and in line on EBITDA.
EBITDA (earnings before interest, tax, depreciation and amortisation) is a standard measure of operating performance. “Underlying” typically adjusts for non-recurring items, though specific adjustments were not disclosed.
| Metric (FY26) | Consensus | Company steer |
|---|---|---|
| Revenue | £29.2m – £29.6m | Higher end of range |
| Underlying EBITDA | £2.3m | In line |
| H2 trading | n/a | Remains strong |
| Outlook | n/a | Unchanged |
Demand drivers: Patient Choice and NHS “quarter four sprint”
The CEO flags that growth plans remain unaffected by broader concerns about reductions in elective surgery across England. The engine here is Patient Choice – the legal right for NHS patients to choose their care provider. One Health says the vast majority of its activity comes from brand new patients referred by GPs who select One Health through Patient Choice, with year-on-year increases in direct referrals.
In H2, the Company also saw more referrals directly from NHS hospitals, supported by additional funding via the NHS “quarter four sprint” initiative – a push to move internal waiting list patients for quicker treatment. That dual-channel demand – GP-chosen new patients plus hospital transfers – underpins the strong H2 commentary.
The strategic backdrop is obvious: the NHS waiting list sits at around 7.3 million, and One Health’s specialisms – notably spine and orthopaedics (hips and knees especially) – are exposed to structural demand from an ageing, less active, and more overweight population.
First surgical hub: planning nearly cleared, shovels ready
One Health expects the final pre-commencement planning condition, related to environmental matters, to be confirmed within weeks. The other six pre-commencement conditions are already satisfied. With contractors ready, the Board still anticipates a one-year construction timetable once sign-offs land.
Why it matters: the hub is expected to add significant surgical capacity and has the potential to materially enhance revenue and profitability. Bringing more capacity under One Health’s umbrella can improve scheduling, throughput, and potentially margins over time. The Company has not disclosed capex, funding structure, or expected returns for the hub, so we will need those details post-approval or at the next results.
Operational footprint: scale, scope, and momentum
To March 2025, One Health treated 17,020 new patients, delivered over 42,000 consultations, and performed over 7,000 surgical procedures. It engages 80 NHS consultants (excluding anaesthetists) and works with 100+ professionals across 9 independent hospitals and 37 outreach clinics. Revenue is drawn from 60+ NHS commissioning bodies and contracts with local NHS hospital trusts.
The core focus areas are orthopaedics, spine, general surgery and gynaecology, with urology added at the end of FY25. The Company concentrates on regions where NHS need is under-supplied and private insurance/self-pay levels are relatively low, currently across Yorkshire, Lincolnshire, Derbyshire, Nottinghamshire and Leicestershire.
Positives to underline from this update
- H2 remains strong; FY26 outlook unchanged – that removes a near-term worry and supports confidence into year-end.
- Revenue tracking to the top end of consensus – helpful signal on demand and execution.
- Dual referral engines – growing GP Patient Choice referrals and increased H2 hospital transfers via the NHS “quarter four sprint”.
- First surgical hub is primed – final environmental condition expected within weeks, one-year build planned, contractors ready. A clear capacity and profit catalyst once live.
- Well funded to continue organic growth and execute the hub rollout, per the outlook statement. Specific cash or net debt figures were not disclosed.
What to watch and the key risks
- Planning sign-off timing – guidance is “within weeks”, but any slippage would push the hub timeline.
- Hub economics – capex, funding mix, start-up phasing and margin impact are not disclosed. Expect more detail after final approvals.
- NHS environment – while management says activity is unaffected by wider elective surgery reductions, policy and funding rhythms can change. One Health’s broad commissioner base (60+) helps, but the Company remains tied to NHS demand and budget dynamics.
- Workforce and capacity – scaling surgeons, anaesthetists and theatre slots is essential. The Company notes a strong pipeline of new surgeons and additional capacity across independent hospitals.
- Profit conversion – underlying EBITDA guidance is £2.3 million; margins and any one-offs are not disclosed. Watch cost discipline and case mix.
My take: steady performance with a clear capacity catalyst
This is a tidy mid-year check-in. No fireworks, which is the point: strong H2, guidance intact, and revenue nudging the top end of forecasts. In a market jittery about elective volumes, that’s a reassuring data point. The combination of Patient Choice demand and targeted hospital transfers is doing the work.
The hub is the swing factor. With final planning clearance almost done and a one-year build, investors get a visible route to more capacity and potentially better margins. The lack of disclosed capex and return metrics is the one obvious gap – not unusual pre-approval, but it will matter once spades hit the ground.
Near term, I’ll be watching for the formal planning sign-off, a firm construction start date, and any early detail on hub economics. Into results, the focus shifts to cash, margins, and how quickly the hub can translate into throughput once operational. For now, this reads as a confident, operationally disciplined update from a trusted NHS partner of 21 years, positioned against a long waiting list and durable procedural demand.
